JP2024513999A5 - - Google Patents
Info
- Publication number
- JP2024513999A5 JP2024513999A5 JP2023563063A JP2023563063A JP2024513999A5 JP 2024513999 A5 JP2024513999 A5 JP 2024513999A5 JP 2023563063 A JP2023563063 A JP 2023563063A JP 2023563063 A JP2023563063 A JP 2023563063A JP 2024513999 A5 JP2024513999 A5 JP 2024513999A5
- Authority
- JP
- Japan
- Prior art keywords
- mrna
- vaccine according
- respiratory viral
- antigenic polypeptide
- encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163175007P | 2021-04-14 | 2021-04-14 | |
| US63/175,007 | 2021-04-14 | ||
| US202163242346P | 2021-09-09 | 2021-09-09 | |
| US63/242,346 | 2021-09-09 | ||
| PCT/US2022/024669 WO2022221440A1 (en) | 2021-04-14 | 2022-04-13 | Influenza-coronavirus combination vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513999A JP2024513999A (ja) | 2024-03-27 |
| JP2024513999A5 true JP2024513999A5 (enExample) | 2025-04-21 |
Family
ID=81579694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563063A Pending JP2024513999A (ja) | 2021-04-14 | 2022-04-13 | インフルエンザ－コロナウイルス組み合わせワクチン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240226277A1 (enExample) |
| EP (1) | EP4322994A1 (enExample) |
| JP (1) | JP2024513999A (enExample) |
| AU (1) | AU2022258463A1 (enExample) |
| WO (1) | WO2022221440A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| CN108430456B (zh) | 2015-10-22 | 2022-01-18 | 摩登纳特斯有限公司 | 癌症疫苗 |
| MD3718565T2 (ro) | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| JP6983455B2 (ja) | 2016-09-14 | 2021-12-17 | モデルナティーエックス， インコーポレイテッド | 高純度ｒｎａ組成物及びその調製のための方法 |
| CN110167587A (zh) | 2016-11-11 | 2019-08-23 | 摩登纳特斯有限公司 | 流感疫苗 |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018187590A1 (en) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
| WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
| CN111212905A (zh) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | Rna聚合酶变体 |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| JP2022521094A (ja) | 2019-02-20 | 2022-04-05 | モデルナティエックス インコーポレイテッド | 共転写キャッピング用ｒｎａポリメラーゼバリアント |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
| WO2022150717A1 (en) | 2021-01-11 | 2022-07-14 | Modernatx, Inc. | Seasonal rna influenza virus vaccines |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| TW202430206A (zh) * | 2022-10-17 | 2024-08-01 | 德商拜恩技術股份公司 | 組合疫苗 |
| CN121568715A (zh) * | 2023-05-10 | 2026-02-24 | 思齐乐私人有限公司 | 组合疫苗 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1903054A3 (de) | 2001-06-05 | 2008-07-23 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| WO2009003222A1 (en) | 2007-06-29 | 2009-01-08 | Commonwealth Scientific And Industrial Research Organisation | Methods for degrading toxic compounds |
| EP3156414B1 (en) | 2007-09-26 | 2019-12-04 | Intrexon Corporation | Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression |
| CN103911378A (zh) | 2007-12-11 | 2014-07-09 | 斯克利普斯研究所 | 涉及mRNA翻译增强因子的组合物和方法 |
| PT2717893T (pt) | 2011-06-08 | 2019-08-20 | Translate Bio Inc | Composições de nanopartículas lipídicas e métodos para transferência de arnm |
| WO2013185069A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| EP4614148A3 (en) | 2013-03-15 | 2025-12-17 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| AU2014310933B2 (en) | 2013-08-21 | 2020-05-14 | CureVac SE | Method for increasing expression of RNA-encoded proteins |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| CN111304231A (zh) | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| WO2015101415A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Artificial nucleic acid molecules |
| MD3718565T2 (ro) * | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| CN111212905A (zh) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | Rna聚合酶变体 |
| JP2022521094A (ja) | 2019-02-20 | 2022-04-05 | モデルナティエックス インコーポレイテッド | 共転写キャッピング用ｒｎａポリメラーゼバリアント |
| KR20230013274A (ko) * | 2020-05-21 | 2023-01-26 | 백세스 테크놀로지스, 인코포레이티드 | 백신 방출을 위한 조성물 및 장치 및 그의 용도 |
| CN116322758A (zh) * | 2020-05-29 | 2023-06-23 | 库尔维科欧洲股份公司 | 基于核酸的组合疫苗 |
| GB2596820A (en) * | 2020-07-07 | 2022-01-12 | Spicona Inc | Combination vaccine |
| CN112546211A (zh) * | 2020-10-23 | 2021-03-26 | 嘉晨西海(杭州)生物技术有限公司 | 基于mRNA的针对冠状病毒和流感病毒的联合疫苗及其制备方法 |
-
2022
- 2022-04-13 WO PCT/US2022/024669 patent/WO2022221440A1/en not_active Ceased
- 2022-04-13 US US18/555,130 patent/US20240226277A1/en active Pending
- 2022-04-13 AU AU2022258463A patent/AU2022258463A1/en active Pending
- 2022-04-13 EP EP22720863.4A patent/EP4322994A1/en active Pending
- 2022-04-13 JP JP2023563063A patent/JP2024513999A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024514182A5 (enExample) | ||
| Serradell et al. | Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins | |
| JP5331340B2 (ja) | インフルエンザウィルスワクチン組成物、及びその使用方法 | |
| TW202233232A (zh) | 遞送mRNA疫苗的脂質奈米顆粒 | |
| JP2024503698A5 (enExample) | ||
| JP7817257B2 (ja) | ｍＲＮＡワクチンを送達するための脂質ナノ粒子 | |
| Wohlbold et al. | Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice | |
| US6780421B1 (en) | Adjuvant for a vaccine composition | |
| Garçon et al. | Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach | |
| JP2011504486A5 (enExample) | ||
| Ibañez et al. | M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A | |
| JP6185548B2 (ja) | インフルエンザワクチンの製造方法 | |
| Gupta et al. | A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases | |
| JP2009539965A5 (enExample) | ||
| JP2017035093A5 (enExample) | ||
| Fotouhi et al. | Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus | |
| TW201427686A (zh) | 改良之疫苗組成物及使用方法 | |
| Lau et al. | The contribution of systemic and pulmonary immune effectors to vaccine-induced protection from H5N1 influenza virus infection | |
| JP2015500854A5 (enExample) | ||
| JP2009514839A5 (enExample) | ||
| Chaparian et al. | A virion-based combination vaccine protects against influenza and SARS-CoV-2 disease in mice | |
| JP2024015475A (ja) | コロナウイルスワクチン | |
| JP2024150687A (ja) | アジュバントおよび該アジュバントを含むワクチン | |
| Zhang et al. | DNA-based influenza vaccines as immunoprophylactic agents toward universality | |
| Abdoli et al. | An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice |